Between 96,000 and 450,000 Americans may be affected by alpha-gal syndrome. This condition was once viewed as a medical curiosity but is now reported regularly.
No participants in a study of 64 adults required emergency epinephrine for food-triggered reactions while treated with omalizumab. These findings were presented on November 12, 2026, in Phoenix.
The study evaluated patients treated between April 2022 and November 2025. All subjects met criteria including compatible clinical histories and positive alpha-gal-specific IgE serologies.
Treating Alpha-gal Syndrome
Alpha-gal syndrome stems from a sugar molecule called galactose-alpha-1,3-galactose. This molecule is found in the saliva of the lone star tick, or Amblyomma americanum.
“If you have less IgE, it's going to take a much higher dose of an allergen to trigger a reaction,” said Dr. Erin McGintee, an allergy and immunology specialist at ENT & Allergy Associates and Stony Brook Medicine tick-borne disease adviser.
The molecule sensitizes the immune system to red meats like beef, pork, and lamb. Dairy products and gelatin also trigger the immune response.
The syndrome often produces delayed reactions. Patients experience hives, gastrointestinal distress, or anaphylaxis several hours after consumption.

Researchers monitored secondary outcomes like changes in reaction burden and mammalian product reintroduction. The study was a retrospective cohort with inherent observational limitations.
Authors suggested that future prospective controlled clinical trials should examine specific markers. They should also study the frequency of anaphylaxis and epinephrine use to confirm these therapeutic links.
“These findings suggest that omalizumab may offer an important additional option for patients who continue to experience reactions,” said Collette Tilly. Tilly is an immunology and allergy fellow at the University of North Carolina at Chapel Hill who headed the research.
Aarti Pandya is the medical director of the Food Allergy Center at Children’s Mercy in Kansas City. She said the results are encouraging. She added that raising the reaction threshold is not the same as eliminating the underlying allergy.
Evaluating Patient Improvements
Approximately 31% of the cohort successfully reintroduced some mammalian foods or products. Clinicians warn that such reintroduction is not safe without direct oversight from an allergist.
Omalizumab is approved for asthma, chronic hives, and certain food allergies. It is not specifically approved for alpha-gal syndrome.

Supinda Bunyavanich is a professor in allergy and systems biology at Mount Sinai Health System. She said the findings were based on a retrospective analysis.
“If it were shown in a prospective trial to help reduce sensitivity [to red meat], I think that would go a long way in terms of improving the lives and the safety of people who live with alpha-gal syndrome,” said Dr. Supinda Bunyavanich, a professor in allergy and systems biology at Mount Sinai Health System.
The ACAAI 2026 program addressed evidence-based practice. The latest Food Allergy Practice Parameter is under development. The GRADE system will determine the strength of future recommendations. It rates the certainty of evidence as high, moderate, low, or very low.
Risks for Agricultural Workers
The syndrome burden is acute for agricultural workers. A study in the Journal of Agromedicine surveyed over 200 farmers and ranchers across 26 states.
Individuals had an average of three healthcare provider visits before diagnosis. Some reported more than 10 visits.

Shaun Cross is an assistant professor at the University of Nebraska Medical Center. He said the condition is challenging for farmers. It sometimes forces them to hire help or stop farming altogether.
Cross shared these findings during the inaugural National Convening on a National Strategy for Alpha-gal Syndrome. Food Allergy Research and Education organized the event.
Experts advise that for those in high-risk areas, the most effective protection is the use of tick repellents. People should check for ticks after spending time outdoors.
Studying Future Preventive Therapies
Scientists are investigating the mechanisms of the condition. They have searched for antibodies that could attach to molecules involved in the allergic response to stop it.
A team identified 13 antibodies targeting molecules linked to allergic responses in recent lab testing. “This discovery … is the first step in potentially identifying ways to prevent AGS and develop new targeted therapies for people before they are affected by this disabling condition,” said Dr. John Powers. Powers is the acting director of the NIH’s National Institute of Allergy and Infectious Diseases.
Readers should consult with a qualified allergist or medical professional to discuss symptoms and management strategies. Individual sensitivity varies considerably. Patients should seek guidance from specialists rather than relying on generalized dietary advice or unverified treatment approaches. It is not yet known which specific therapeutic protocol will be adopted for widespread clinical use.
Worth a look
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.